NCT07013461 International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
| NCT ID | NCT07013461 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong-Shenzhen Hospital |
| Condition | Nasopharyngeal Cancinoma (NPC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2026-01-09 |
| Primary Completion | 2031-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2026-01-09 with a primary completion date of 2031-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this international, multicenter, prospective observational study is to improve prognostication and prediction of failure pattern for nasopharyngeal carcinoma (NPC), in order to provide more accurate guidance for personalized treatment decision. Firstly, we aim to improve the fundamental TNM staging system \[The American Joint Committee on Cancer(AJCC)/Union for International Cancer Control(UICC) TNM Version-Nine\] based on universally assessable anatomical parameters. Secondly, we aim to further refine prognostication for individual patients by integrating anatomical TNM parameters with non-anatomical factors and molecular biomarkers. In addition to the core group of participating centers from China (including Hong Kong) where NPC is most prevalent, the study will enrol patients from multiple countries/regions including those from non-endemic areas to provide global data. Patients treated with contemplary treatment methods during October 2025 to September 2026 will be recruited and they will be followed up for 5 years to generate detailed records for robust evaluation. Key Questions: * To achieve optimal improvement of anatomically based AJCC/UICC TNM Classification for global application * To achieve precise prediction of failure pattern for individual patients by integration of TNM system and non-anatomical prognostic factors/molecular biomarkers Recruited patients with confirmed histological diagnosis of NPC will undergo standard clinical evaluations and receive treatment per institutional guidelines. The anatomical extent of disease at presentation will be evaluated by experienced radiologists and oncologists. The patient will be followed up for 5 years and clinical outcome will be recorded for analyses on correlation with prognostic factors. This study will be another important milestone for NPC staging because firstly, this is the first time that the data are based on prospective data to ensure comprehensive coverage of all essential evidence; and secondly, this is the first time that centers from non-endemic countries/regions will also participate to ensure that the final recommendations are globally applicable. The findings will provide valuable evidence for the development of the AJCC/UICC TNM Version-Ten staging system and prognostic system to improve risk stratification for designing personalized treatment strategy, ultimately leading to improvement of patient outcome and patient selection for future research worldwide.
Eligibility Criteria
Inclusion Criteria: * All histologically confirmed nasopharyngeal carcinoma treated between 1 Oct 2025 and 30 Sep 2026 Exclusion Criteria: * Non-epithelial tumors of nasopharynx (including lymphoma, sarcoma of soft tissue, bone/cartilagetumors. mucosal melanoma, salivary type tumors)
Frequently Asked Questions
Who can join the NCT07013461 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasopharyngeal Cancinoma (NPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07013461 currently recruiting?
Yes, NCT07013461 is actively recruiting participants. Visit ClinicalTrials.gov or contact The University of Hong Kong-Shenzhen Hospital to inquire about joining.
Where is the NCT07013461 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07013461 clinical trial?
NCT07013461 is sponsored by The University of Hong Kong-Shenzhen Hospital. The trial plans to enroll 5,000 participants.